A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies
A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Listed as NCT00000869, this PHASE3 trial focuses on HIV Infections and Pregnancy and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 7 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States, Augusta, United States, Baltimore, United States, Bayamón, Puerto Rico, Birmingham, United States, Boston, United States, Camden, United States, Charleston, United States, Chicago, United States, Columbus, United States and 35 more location s